Aspira Pathlab & Diagnostics has informed that it enclosed disclosure, Form - C pursuant to Regulation 7(2) read with Regulation 6(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015 from MJay Arvind Bhanushali, Promoters Immediate Relative of the Company for the acquisition of Equity Shares from the market as on March 14, 2024 and March 15, 2024 respectively.
The above information is a part of company’s filings submitted to BSE.